Uptake of breast cancer prevention and screening trials
Uptake of breast cancer prevention and screening trials
复制标题
DOI：
10.1136/jmg.2010.082768
复制
发表时间：
2010-12-01
影响因子：
4
通讯作者：
Howell, Anthony
中科院分区：
文献类型：
--
作者：
Evans, D. Gareth;Harvie, Michelle;Howell, Anthony
背景癌症试验，特别是预防性试验的接受率在全球范围内一直令人失望。方法对三项随机化疗乳腺癌预防试验和两项在家族风险增加的妇女中进行的饮食预防试验的接受率进行评估，并与一系列风险类别的筛查试验的接受率进行比较。结果药物预防试验的接受率仍然很低，为5.3- 13.6%，但是对于IBIS 1和IBIS 2组合，高风险组（12%）显著高于极高风险组（8.4%）（p=0.004）。两项饮食预防研究通过邮寄招募的比例也低得令人不安，分别为6.2%和12.5%。相比之下，两个乳房X线摄影筛查试验在所有风险类别中的摄取率>90%。结论如果要将预防试验视为降低风险的手术的可行替代方案，则必须做更多的工作来改善预防试验的招募。
Background Uptake of cancer trials and in particular prevention trials has been disappointing globally.Methods Uptake to three randomised chemotherapy breast cancer prevention trials and two dietary prevention trials in women at increased familial risk were assessed and compared with uptake of screening trials across a range of risk categories.Results Uptake of drug prevention trials remains low at 5.3-13.6%, but is significantly higher in the high (12%) compared to very high risk group (8.4%) for IBIS1 and IBIS2 combined (p=0.004). Recruitment to two dietary prevention studies via mail shot was also disappointingly low at 6.2% and 12.5%. In contrast uptake to two mammography screening trials was >90% in all risk categories.Conclusions More work must be done to improve recruitment to prevention trials if they are to be seen as viable alternatives to risk reducing surgery.Impact Trial designs and decision aids need to be developed to improve recruitment.